TScan Therapeutics Inc TCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TCRX is a good fit for your portfolio.
News
-
TScan Gets FDA Clearance of Investigational New Drug Application for Cancer Treatment
-
TScan Therapeutics Shares Rise 17% After FDA Clears IND for Cancer Treatment
-
Stocks to Watch: Marvell Technology, Workday, Gap, TScan Therapeutics
-
TScan Therapeutics Shares Take Flight on Amgen Pact
-
Amgen, TScan Therapeutics Set Crohn's Disease Collaboration
-
TScan Therapeutics stock soars after Amgen collaboration on Crohn's disease treatment that could bring in more than $500 million
Trading Information
- Previous Close Price
- $8.99
- Day Range
- $8.86–9.36
- 52-Week Range
- $1.93–9.36
- Bid/Ask
- $8.92 / $8.97
- Market Cap
- $472.06 Mil
- Volume/Avg
- 350,461 / 210,134
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 24.96
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 154
- Website
- https://www.tscan.com
Comparables
Valuation
|
Metric
|
TCRX
|
ALLK
|
ARVN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.54 | 1.01 | 3.51 |
Price/Sales | 24.96 | — | 16.47 |
Price/Cash Flow | — | — | — |
Price/Earnings
TCRX
ALLK
ARVN
Financial Strength
|
Metric
|
TCRX
|
ALLK
|
ARVN
|
|---|---|---|---|
Quick Ratio | 5.17 | 3.88 | 4.89 |
Current Ratio | 5.23 | 4.11 | 4.94 |
Interest Coverage | −27.14 | — | — |
Quick Ratio
TCRX
ALLK
ARVN
Profitability
|
Metric
|
TCRX
|
ALLK
|
ARVN
|
|---|---|---|---|
Return on Assets (Normalized) | −35.04% | −54.70% | −25.64% |
Return on Equity (Normalized) | −63.78% | −73.03% | −55.39% |
Return on Invested Capital (Normalized) | −41.55% | −64.58% | −61.56% |
Return on Assets
TCRX
ALLK
ARVN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fwwqdlxr | Yncmh | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ydjsskf | Flptdk | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dvxwfpgl | Zqdfy | $107.6 Bil | |
MRNA
| Moderna Inc | Nngvfnmcx | Zncj | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Wjnvchx | Kgyh | $22.2 Bil | |
ARGX
| argenx SE ADR | Wfpwsgxgm | Vcc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jjtmzfwmb | Nfxnqgl | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pddrzrkp | Mhkbv | $15.1 Bil | |
INCY
| Incyte Corp | Nlqbtwrg | Nrbwkb | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lvrlbzfgq | Qqqbpy | $12.7 Bil |